

27 MAR 2006

P-10/10/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	Unknown
		Filing Date	Herewith
		First Named Inventor	Kuhara, et al
		Art Unit	Unknown
(Multiple sheets used when necessary)		Examiner	Unknown
SHEET 1 OF 1		Attorney Docket No.	TOYA108.014APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
					T ¹

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
<i>Re</i>		Kasaian, et al. "Cyclosporin a Inhibition of Interleukin 2 Gene Expression, But Not Natural Killer Cell Proliferation, After Interferon Induction In Vivo," <i>Journal of Experimental Medicine</i> , Vol. 171, pp. 745-762, 1990.			
		Kuhara, et al. "Oral Administration of Lactoferrin Raises NK Cell Activity in Mice," <i>Milk Science</i> , Vol. 53, No. 4, pp. 262-264, 2004.			
		Riccardi, et al. "Generation of Mouse Natural Killer (NK) Cell Activity: Effect of Interleukin-2 (IL-2) and Interferon (IFN) on the <i>In Vivo</i> Development of Natural Killer Cells From Bone Marrow (BM) Progenitor Cells," <i>International Journal of Cancer</i> , Vol. 38, pp. 553-562, 1986.			
		Tsuda, et al. "Inhibition of Carcinogenesis by Bovine Lactoferrin and Analysis of Mechanisms," <i>FFI Journal</i> , No. 200, pp. 27-35, 2002 (in Japanese).			
		Tsuda, et al. "Cancer Prevention by Bovine Lactoferrin and Underlying Mechanisms—A Review of Experimental and Clinical Studies," <i>Biochem. Cell Biol.</i> , Vol. 80, pp. 131-136, 2002			
		Wang, et al. "Activation of Intestinal Mucosal Immunity in Tumor-Bearing Mice by Lactoferrin" <i>Japanese Journal of Cancer Research</i> , Vol. 91, pp. 1022-1027, October 2000.			
		International Search Report dated September 28, 2005 (in Japanese).			

2472561
032306

Examiner Signature	<i>Darsse</i>	Date Considered	7-26-07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/573,564
		Filing Date	March 27, 2006
		First Named Inventor	Kuhara, et al.
		Art Unit	1647
(Multiple sheets used when necessary)		Examiner	Landsman, Robert S.
SHEET 1 OF 1		Attorney Docket No.	TOYA108.014APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
PL		Sivori, et al. "CpG and Double-Stranded RNA Trigger Human NK Cells by Toll-Like Receptors: Induction of Cytokine Release and Cytotoxicity Against Tumors and Dendritic Cells," PNAS, Vol. 101, No. 26, 10116-10121, July 6, 2004.			

3890816
061507

Examiner Signature	<i>Landsman</i>	Date Considered	7-26-07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i> SHEET 1 OF 1		Application No.	10/573,564
		Filing Date	March 27, 2006
		First Named Inventor	Kuhara, et al.
		Art Unit	Unknown
Examiner	Unknown		
		Attorney Docket No.	TOYA108.014APC

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
PL		JP 2001-503430	03/13/01	Wisconsin Alumni Research Foundation		PCT 1 st Pg
		JP 2002-515893	05/28/02	Pharming B.V.		PCT 1 st Pg
		JP 2001-149069	06/05/01	Inst of Physical & Chemical Res		Abstract
		WO 98/19675	05/14/98	Wisconsin Alumni Research Foundation		
↓		WO 98/33509	08/06/98	Pharming BIV.		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ¹
PL		Porgador, et al. "Natural Killer Cell Lines Kill Autologous β_2 -Microglobulin-Deficient Melanoma Cells: Implications for Cancer Immunotherapy," Proc. Natl. Acad. Sci., USA, Vol. 94, pp. 13140-13145, 1997.				
↓		Molecular Medicine, Vol. 39, pp. 238-246, 2002. Hemmi and Akira				Partial
↓		Molecular Medicine, Vol. 40, pp. 186-193, 2003. Akira S				Partial

 2619649
 052206

Examiner Signature	<i>Loctse</i>	Date Considered	7-26-07
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

 T¹ - Place a check mark in this area when an English language Translation is attached.